Oral GLP-1 Drugs: Novo Nordisk, Eli Lilly Eye India Launch In 2027 | Pharma Stocks In Focus

The race for oral obesity drugs is heating up as pharma giants Novo Nordisk and Eli Lilly prepare to bring GLP-1 pills to markets including India. Mayuresh Joshi, Head Equity Research, William O’Neil India, explains the growing opportunity in oral anti-obesity medicines and highlights companies that could benefit from the expansion of the GLP-1 market. The discussion also covers Dr Reddy’s, Cipla and ancillary players, along with the potential for the global GLP-1 market to grow sharply over the next four to five years. Business Today’s Neetu Chandra Sharma brings the latest updates on the expected India launch timeline and regulatory approvals.